Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT06061042 Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT06061042
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to give their informed consent to participate in the study.
  • People with a Body Mass Index (BMI) above 30 kg/m² (a measure that indicates obesity).
  • People who have insulin resistance (shown by a fasting blood insulin level above 62 pmol/L) and/or prediabetes (shown by a fasting blood sugar level between 5.3 and 7.0 mmol/L).
  • People whose weight has remained stable for the 3 months before joining the study.
  • Women who have gone through menopause (at least 1 year since their last period).

Who may not be able to join:

  • People who take any medications, except for those used to treat metabolic syndrome (a group of conditions including high blood pressure, high blood sugar, and excess body fat).
  • People who have a medical condition that could affect the study's results or design.
  • People who have a history of any psychiatric disorder, including eating disorders.
  • People who work shift work (irregular or rotating work hours).
  • People who do intensive sport or exercise for more than 3 hours per week.
  • People who currently smoke.
  • People who misuse drugs or drink more than 3 units of alcohol per day.
  • People who have a medical reason why they cannot have an MRI scan.
  • People with a known intolerance to lactose or gluten.
  • People with a known allergy to soy, eggs, milk, or peanuts.
  • People whose obesity began in childhood.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mireille JM Serlie, MD PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phone: +31 683238752

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Registry
ClinicalTrials.gov
Start date
1 October 2023
Est. completion
1 December 2027

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Insulin Sensitivity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov